These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 24073274)
41. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. Logtenberg MEW; Jansen JHM; Raaben M; Toebes M; Franke K; Brandsma AM; Matlung HL; Fauster A; Gomez-Eerland R; Bakker NAM; van der Schot S; Marijt KA; Verdoes M; Haanen JBAG; van den Berg JH; Neefjes J; van den Berg TK; Brummelkamp TR; Leusen JHW; Scheeren FA; Schumacher TN Nat Med; 2019 Apr; 25(4):612-619. PubMed ID: 30833751 [TBL] [Abstract][Full Text] [Related]
42. Inflammation-induced proteolytic processing of the SIRPα cytoplasmic ITIM in neutrophils propagates a proinflammatory state. Zen K; Guo Y; Bian Z; Lv Z; Zhu D; Ohnishi H; Matozaki T; Liu Y Nat Commun; 2013; 4():2436. PubMed ID: 24026300 [TBL] [Abstract][Full Text] [Related]
43. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Barclay AN; Van den Berg TK Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318 [TBL] [Abstract][Full Text] [Related]
44. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology. Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171 [TBL] [Abstract][Full Text] [Related]
49. CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies. Bouwstra R; van Meerten T; Bremer E Clin Transl Med; 2022 Aug; 12(8):e943. PubMed ID: 35908284 [TBL] [Abstract][Full Text] [Related]
50. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231 [No Abstract] [Full Text] [Related]
51. The CD47-SIRPα signalling system: its physiological roles and therapeutic application. Murata Y; Kotani T; Ohnishi H; Matozaki T J Biochem; 2014 Jun; 155(6):335-44. PubMed ID: 24627525 [TBL] [Abstract][Full Text] [Related]
52. CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Zhao XW; van Beek EM; Schornagel K; Van der Maaden H; Van Houdt M; Otten MA; Finetti P; Van Egmond M; Matozaki T; Kraal G; Birnbaum D; van Elsas A; Kuijpers TW; Bertucci F; van den Berg TK Proc Natl Acad Sci U S A; 2011 Nov; 108(45):18342-7. PubMed ID: 22042861 [TBL] [Abstract][Full Text] [Related]
53. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362 [TBL] [Abstract][Full Text] [Related]
55. Anti-tumor effect of PTEN and its effect on inhibition of the bone tumor through the CD47-SIRPα signaling pathway. Zhang Y; Hao J Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):40-44. PubMed ID: 38279488 [TBL] [Abstract][Full Text] [Related]
56. 'Clustering' SIRPα into the plasma membrane lipid microdomains is required for activated monocytes and macrophages to mediate effective cell surface interactions with CD47. Ha B; Lv Z; Bian Z; Zhang X; Mishra A; Liu Y PLoS One; 2013; 8(10):e77615. PubMed ID: 24143245 [TBL] [Abstract][Full Text] [Related]
57. Notch Signaling Modulates Macrophage Polarization and Phagocytosis Through Direct Suppression of Signal Regulatory Protein α Expression. Lin Y; Zhao JL; Zheng QJ; Jiang X; Tian J; Liang SQ; Guo HW; Qin HY; Liang YM; Han H Front Immunol; 2018; 9():1744. PubMed ID: 30105024 [TBL] [Abstract][Full Text] [Related]
58. Dual-Action Protein-siRNA Conjugates for Targeted Disruption of CD47-Signal Regulatory Protein α Axis in Cancer Therapy. Lee JW; Yoon HY; Ko YJ; Kim EH; Song S; Hue S; Gupta N; Malin D; Kim J; Kong B; Kim S; Kim IS; Kwon IC; Yang Y; Kim SH ACS Nano; 2024 Aug; 18(33):22298-22315. PubMed ID: 39117621 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRPalpha), CD47, and SHP-1. Florian S; Ghannadan M; Mayerhofer M; Aichberger KJ; Hauswirth AW; Schernthaner GH; Printz D; Fritsch G; Böhm A; Sonneck K; Krauth MT; Müller MR; Sillaber C; Sperr WR; Bühring HJ; Valent P J Leukoc Biol; 2005 Jun; 77(6):984-92. PubMed ID: 15784688 [TBL] [Abstract][Full Text] [Related]
60. Neuronal signal-regulatory protein alpha drives microglial phagocytosis by limiting microglial interaction with CD47 in the retina. Jiang D; Burger CA; Akhanov V; Liang JH; Mackin RD; Albrecht NE; Andrade P; Schafer DP; Samuel MA Immunity; 2022 Dec; 55(12):2318-2335.e7. PubMed ID: 36379210 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]